In the past 3 years, multiple studies have shown increased levels of plasma p-tau in patients with a clinical diagnosis of probable AD dementia compared to non-AD diagnoses or cognitively unimpaired individuals [1–6]. This evidence concerns the gene MAPT and Alzheimer disease.